• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparison of new adenosine diphosphate receptor antagonists with clopidogrel in patients with coronary artery disease: a meta-analysis
Abstract Recent data suggest the superiority of new adenosine diphosphate (ADP) receptor antagonists compared with clopidogrel in acute coronary syndrome patients. We aimed to assess the risks and benefits of new ADP receptor antagonists in patients with coronary artery disease (CAD). Relevant studies published through February 28, 2014 were searched and identified in the MEDLINE, EMBASE, and Cochrane databases. Summary estimates were obtained using a random-effects model. All nine published randomized controlled studies comparing new ADP receptor antagonists with clopidogrel in CAD were included. The database con...
Source: Heart and Vessels - November 6, 2014 Category: Cardiology Source Type: research

Prasugrel, a Third-Generation P2Y12 Receptor Antagonist, in Patients With Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention.
Conclusions:These results support the risk-benefit profile of an adjusted dosing regimen of prasugrel in Japanese patients undergoing PCI. Larger studies are required to confirm these findings. PMID: 25342212 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 21, 2014 Category: Cardiology Authors: Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Saito S Tags: Circ J Source Type: research

Treatment patterns, risk factor control and functional capacity in patients with cardiovascular and chronic kidney disease in the cardiac rehabilitation setting
Conclusion Within a short period of 3–4 weeks, CR led to substantial improvements in key risk factors such as lipid profile, blood pressure, and physical fitness for all patients, even if CKD was present.
Source: European Journal of Preventive Cardiology - August 18, 2014 Category: Cardiology Authors: Voller, H., Gitt, A., Jannowitz, C., Karoff, M., Karmann, B., Pittrow, D., Reibis, R., Hildemann, S. Tags: Original scientific papers Source Type: research

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
Conclusion In patients with NSTE-ACS, benefit of ticagrelor over clopidogrel in reducing ischaemic events and total mortality was consistent with the overall PLATO trial, independent of actually performed revascularization during the initial 10 days.
Source: European Heart Journal - August 14, 2014 Category: Cardiology Authors: Lindholm, D., Varenhorst, C., Cannon, C. P., Harrington, R. A., Himmelmann, A., Maya, J., Husted, S., Steg, P. G., Cornel, J. H., Storey, R. F., Stevens, S. R., Wallentin, L., James, S. K. Tags: Acute coronary syndromes Source Type: research

Who might benefit from early aspirin after coronary artery surgery?
A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether early administration of aspirin might optimize vein graft patency. More than 250 papers were found using the reported search, of which 4 new papers in addition to the previous 7 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Early postoperative aspirin administered within 6 h following coronary artery bypass grafting (CABG) has been show...
Source: Interactive CardioVascular and Thoracic Surgery - August 14, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Gukop, P., Gutman, N., Bilkhu, R., Karapanagiotidis, G. T. Tags: Cardiac - physiology, Education, Congestive Heart Failure, Molecular biology Adult Cardiac Source Type: research

Abstract 132: The POWR Survey: Patient and Physician Perspectives on Outcomes Weighting in Revascularization. Session Title: Poster Session I
Conclusions: Patients and physicians agree on which outcomes are most (death and stroke)and least impactful (incision scar), but there is a lot of variability in between supporting the reporting of more adverse outcomes and not just those included in MACE.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Pandit, J. A., Gupta, V., Boyer, N., Ports, T. A., Yeghiazarians, Y., Boyle, A. J. Tags: Session Title: Poster Session I Source Type: research

Efficacy and Safety of Adjusted-Dose Prasugrel Compared With Clopidogrel in Japanese Patients With Acute Coronary Syndrome.
Conclusions: Prasugrel 20/3.75mg was associated with a low incidence of ischemic events, similar to the results of TRITON-TIMI 38, and with a low risk of clinically serious bleeding in Japanese ACS patients. PMID: 24759796 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 22, 2014 Category: Cardiology Authors: Saito S, Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Nakamura M Tags: Circ J Source Type: research

Ticagrelor Effects on Myocardial Infarction and the Impact of Event Adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) Trial
ConclusionsIn patients with ACS, ticagrelor significantly reduced the incidence of MI compared with clopidogrel, with consistent results across most MI subtypes. CEC procedures identified more MI endpoints compared with site investigators. (A Comparison of Ticagrelor [AZD6140] and Clopidogrel in Patients With Acute Coronary Syndrome [PLATO]; NCT00391872)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - April 14, 2014 Category: Radiology Source Type: research

Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Background: Extensive coronary artery disease (CAD) is associated with higher risk. In this substudy of the PLATO trial, we examined the effects of randomized treatment on outcome events and safety in relation to the extent of CAD.Methods: Patients were classified according to presence of extensive CAD (defined as 3-vessel disease, left main disease, or prior coronary artery bypass graft surgery). The trial's primary and secondary end points were compared using Cox proportional hazards regression.Results: Among 15,388 study patients for whom the extent of CAD was known, 4,646 (30%) had extensive CAD. Patients with extensiv...
Source: American Heart Journal - April 14, 2014 Category: Cardiology Authors: Anna Kotsia, Emmanouil S. Brilakis, Claes Held, Christopher Cannon, Gabriel P. Steg, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann Tags: Acute Ischemic Heart Disease Source Type: research

Impact of Dual Antiplatelet Therapy on Outcomes Among Aspirin-Resistant Patients Following Coronary Artery Bypass Grafting
This study was designed to define the impact of dual antiplatelet therapy (dAPT) on clinical outcomes among aspirin-resistant patients who underwent coronary artery surgery. We randomly assigned 219 aspirin-resistant patients according to multiple electrode aggregometry to receive clopidogrel (75 mg) plus aspirin (300 mg) or aspirin-monotherapy (300 mg). The primary end point was a composite outcome of all-cause death, nonfatal myocardial infarction, stroke, or cardiovascular hospitalization assessed at 6 months postoperatively. The primary end point occurred in 6% of patients assigned to dAPT and 10% of patients rando...
Source: The American Journal of Cardiology - March 3, 2014 Category: Cardiology Authors: Hrvoje Gasparovic, Mate Petricevic, Tomislav Kopjar, Zeljko Djuric, Lucija Svetina, Bojan Biocina Tags: Coronary Artery Disease Source Type: research

Characteristics, treatment and one-year outcomes of patients with acute coronary syndrome in a tertiary hospital in India.
CONCLUSIONS: ACS population was older than previously described in India. Evidence-based pharmacotherapy and interventions, and outcomes were comparable to the developed nations. PMID: 24814108 [PubMed - in process]
Source: Indian Heart J - March 1, 2014 Category: Cardiology Authors: Isezuo S, Subban V, Krishnamoorthy J, Pandurangi UM, Janakiraman E, Kalidoss L, Sankardas MA Tags: Indian Heart J Source Type: research

054 * hybrid surgery in patients with concomitant critical coronary and carotid artery lesions
Conclusions: Hybrid surgery in patients with concomitant critical coronary and carotid artery lesions is a safe and very effective procedure that reduces the number of complications during the surgical treatment of this severe cohort of patients.
Source: Interactive CardioVascular and Thoracic Surgery - September 18, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Edemskiy, A., Chernyavskiy, A., Vinogradova, T. E., Chernyavskiy, M. Tags: Controversies in coronary artery surgery II Source Type: research

Clopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial
Conclusions: Clopidogrel is safer than ticagrelor in regard to bleeding. Additionally, ticagrelor's purported faster antiplatelet ‘offset’ is substantially longer than its pharmacokinetics indicate. Considering the fact that the mortality, stent thrombosis and myocardial infarction ‘benefit’ of ticagrelor have recently been challenged, and that the increase in stroke on ticagrelor has recently been shown to be worse than originally published, the decision to use ticagrelor over clopidogrel in the face of a higher risk for bleeds is not advised.
Source: International Journal of Cardiology - July 31, 2013 Category: Cardiology Authors: James J. DiNicolantonio, Fabrizio D'Ascenzo, Ales Tomek, Saurav Chatterjee, Asfandyar K. Niazi, Giuseppe Biondi-Zoccai Tags: Editorials Source Type: research

Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
Conclusions: Prior-CABG patients presenting with acute coronary syndrome are a high-risk cohort for death and recurrent cardiovascular events but have a lower risk for major bleeding. Similar to the results in no-prior-CABG patients, ticagrelor was associated with a reduction in ischemic events without an increase in major bleeding.
Source: American Heart Journal - July 29, 2013 Category: Cardiology Authors: Emmanouil S. Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann, Lars Wallentin, Stefan K. James Tags: Acute Ischemic Heart Disease Source Type: research

Pages: 1  2  3  4